Tacrolimus (FK506)-induced mutism after liver transplant

Pediatric Neurology

Volumn 28, Issue 2, 2003, Pages 156-158

  Sokol, Deborah K ^a,b   Molleston, Jean P ^a   Filo, Ronald S ^a   Van Valer, Joseph ^a   Edwards Brown, Mary ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CEFTAZIDIME; HYDRAZINE; NIFEDIPINE; PHENOBARBITAL; PROPRANOLOL DERIVATIVE; TACROLIMUS; VANCOMYCIN;

AGITATION; ARTICLE; ATAXIA; BACTEREMIA; CASE REPORT; DRUG BLOOD LEVEL; DYSARTHRIA; EYE MOVEMENT; FEMALE; GAZE; HUMAN; HYPERTENSION; LIVER TRANSPLANTATION; MUTISM; NEUROLOGIC DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SEIZURE; SPEECH DISORDER; TREMOR;

EID: 0345700781     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(02)00502-7     Document Type: Article

References (15)

1. Green M.D., Michaels M.G. Tacrolimus Effects and side effects . Pediatr Infect Dis. 18:(4):1999;372-373.
2. Jordan S.C., Rosenthal P., Makowka L. Immunosuppression in organ transplantation. Seminars Pediatr Surg. 2:1993;206-207.
3. McDiarmid S.V., Busuttil N.L., Ascher J., et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Transplantation. 59:1995;530-536.
4. Eelco F.M., Wijdicks M.D., Wiesner M.D., Dahlke L.J., Krom R.A. FK506-induced neurotoxicity in liver transplantation. AnnNeurol. 35:1994;498-501.
5. Margarit C., Rimola A., Gonzalez-Pinto I., et al. Efficacy and safety of oral low dose tacrolimus treatment in liver transplantation. Transpl Int. 11:1998;S260-S266.
6. Chand D.H., Southerland S.M., Cunningham R.J. Tacrolimus The good, the bad and the ugly . Pediatr Transpl. 5:2001;32-36.
7. Reyes J., Gayowski T., Fung J., Todo S., Alessani M., Starzl T.E. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation. 50:1990;1043-1044.
8. Boeve B.F., Kimmel D.W., Aronson A.E., DeGroen P.C. Dysarthria and apraxia of speech associated with FK506. Mayo Clin Proc. 71:1996;969-972.
9. Bronster D.J., Gurkan A., Buchsbaum MS Emre S. Tacrolimus-associated mutism after orthotopic liver transplantation. Transplantation. 70:2000;979-982.
10. Emre S., Genyk Y., Schluger L.K., et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int. 13:2000;73-78.
11. Bronster D.J., Boccagni P., O'Rourke M., Emre S., Schwartz M., Miller C. Loss of speech after orthotopic liver transplantation. Transpl Int. 8:1995;234-237.
12. Duffy J.R. Neurogenic mutism. Duffy J.R. Motor speech disorders: Substrates, differential diagnosis, and management. 1995;282-296 Mosby, St. Louis.
13. Doxey D., Bruce D., Sklar F., Swift D., Shapiro K. Posterior fossa syndrome Identifiable risk factors and irreversible complications . Pediatr Neurosurg. 31:1999;131-136.
14. Hinchey J., Chaves C., Appignani B., et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 334:1996;494-500.
15. Botez M.I., Gravel J., Ezzedine A., Vezina J. Reversible chronic cerebellar ataxia after phenytoin intoxication Possible role of cerebellum in cognitive thought . Neurology. 35:1985;1152-1157.